Artificial intelligence in healthcare sits at the crossroads of rising inflation pressures, higher bond yields, and ongoing geopolitical tension, as investors search for themes tied to real-world problem solving and efficiency. AI tools that help doctors detect disease, personalise treatment, and reduce hospital bottlenecks speak directly to cost control and better patient outcomes, two priorities that tend to matter regardless of the growth or rate cycle. This article highlights three stocks from a Transformative AI Healthcare screener, providing a closer look at companies using data and algorithms to address diagnostics, treatment, and care delivery at scale.

GeneDx Holdings (WGS)

Overview: GeneDx Holdings is a genomics company that provides whole exome and whole genome sequencing for pediatric and rare diseases, using AI to analyze DNA and deliver clinical-grade test reports for rare disease, hereditary risk, and cancer. It also sells data and information services built on its large rare disease dataset.

Operations: GeneDx generates almost all of its US$427.5 million revenue in the United States, with US$423.1 million from its core Gene Dx segment and US$4.5 million from Fabric Genomics and legacy Sema4.

Market Cap: US$2.0b

GeneDx sits at the center of AI driven genomics in pediatrics, with whole exome and genome sequencing supported by a rare disease database and an AI platform that aims to make diagnosis faster and more precise. Analysts expect strong revenue and earnings growth. The stock currently trades well below some fair value estimates and price targets, which may appeal to investors who focus on mispriced growth. At the same time, the company is unprofitable, relies on external funding, and is seeing insider selling, so execution on reimbursement, volume growth, and cost discipline really matters. Recent deals, such as the Zevra NPC testing program and a new term loan, illustrate how GeneDx is trying to scale its model and strengthen its finances.

AI fueled genomics, a rare disease dataset and a stock trading below some fair value estimates can create an intriguing mismatch. See how the 3 key rewards and 1 important warning sign could reshape your view of the trade off hiding in GeneDx.

Pfizer (PFE)

Overview: Pfizer is a global pharmaceutical company that discovers, develops, manufactures, and sells prescription medicines and vaccines for conditions such as cardiovascular disease, migraine, cancer, rare diseases, infections, inflammation, and COVID 19, supported by partnerships with companies like Bristol Myers Squibb, Astellas, Merck KGaA, BioNTech, and others.

Operations: Pfizer generates the bulk of its US$62.2b revenue from its Global Biopharmaceuticals Business at US$61.2b, with smaller contributions from Pfizer Centreone at US$1.3b and Pfizer Ignite at US$41m, and earns US$37.1b in the United States versus US$25.5b across developed and emerging markets.

Market Cap: US$153.6b

Pfizer gives you exposure to artificial intelligence in healthcare through its work on biomolecular AI models, while still being anchored by a broad portfolio of medicines and vaccines in areas like oncology, rare disease, and metabolic health. The pipeline is busy, from obesity and GLP 1 programs and oncology data at ASCO 2026 to a Lyme disease vaccine candidate and priority reviews for cancer combinations. At the same time, the company is also dealing with earnings and revenue expected to decline over the next few years and questions around dividend coverage and debt. For investors weighing that mix of AI enabled R&D, late stage assets, pricing pressure, and patent risk, the full story goes well beyond headline P/E ratios and a high dividend yield.

Pfizer’s AI driven R&D and broad drug portfolio could be masking a very different risk reward profile than headline earnings suggest. Review the full 1 key reward and 4 important warning signs (3 are major!)

Insmed (INSM)

Overview: Insmed develops and commercializes therapies for serious and rare diseases, anchored by ARIKAYCE for difficult lung infections and a late stage pipeline that targets bronchiectasis, pulmonary hypertension, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and other hard to treat conditions across the United States, Europe, Japan, and additional regions.

Operations: Insmed generates US$606.4 million in revenue from developing and commercializing therapies for rare disease patients, with about US$453.0 million from the United States and US$153.5 million from international markets.

Market Cap: US$29.2b

Insmed sits at the intersection of AI driven protein engineering and late stage respiratory drugs. Brensocatib and ARIKAYCE label expansion are viewed as key drivers, alongside broader work in gene therapy and pulmonary hypertension. Analysts project revenue and earnings growth, yet the company is still loss making, carries a very high P/S multiple, and relies on external funding and ongoing share issuance, so execution on brensocatib launches, payer access, and Phase II and III readouts remains important. For investors who can tolerate clinical, regulatory, and dilution risk, the combination of rare disease focus, management continuity, and ambitious guidance on future respiratory revenues may make this a name to watch more closely as AI enabled drug development in complex lung conditions progresses.

Insmed’s AI driven respiratory push, rare disease focus, and high P/S valuation could be telling a very different story than the headlines suggest, and the analyst forecasts for Insmed may reveal the twist investors are missing

The three stocks in this article are just a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaced 30 more AI healthcare names with equally compelling stories around diagnostics, drug discovery, and care delivery. Identify and analyze the companies whose catalysts best match your view on biomolecular AI, real time monitoring, cost savings, and faster clinical development so you can focus on the highest conviction ideas available inside Simply Wall St.

Take Control of Your Investment Journey

If GeneDx Holdings or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your top picks to a Watchlist to monitor the share price against the fair value for the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Today

New ideas do not stay under the radar for long. As money chases the next breakout, the best entry points get caught quickly, so get in early.

• Scan for powerful income plays built to keep paying, and use the curated 13 dividend fortresses to spot yield opportunities before everyone starts chasing them.
• Hunt for resilient names that hold up when sentiment drops, leaning on the hand picked 73 resilient stocks with low risk scores to pinpoint companies with lower risk scores while it still matters.
• Target future facing themes in physical infrastructure by running through the curated 33 power grid technology and infrastructure stocks to catch potential winners in grid technology before momentum really starts flying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.